Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical animal studies with no human data
PubMed 30915550 · doi:10.1007/s00441-019-03016-8
What was done
The authors reviewed published literature investigating the synthetic gastric pentadecapeptide BPC 157 as a therapeutic agent for musculoskeletal soft tissue repair, focusing on preclinical models of tendon, ligament, and skeletal muscle healing.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. It qualitatively reports consistently positive, prompt healing across various soft tissue injury models (both direct trauma and systemic insults like hyperkalemia and hypermagnesemia), with few reported adverse reactions.
Why it matters
BPC 157 represents an investigational candidate for soft tissue healing that may offer practical administration advantages over existing growth factors, especially for hypocellular and hypovascular structures like tendons and ligaments.
Limits
The evidence is almost exclusively derived from small rodent models with zero human clinical efficacy confirmed. Most available research originates from only a few research groups, mechanistic pathways remain unclear, and no meta-analytic pooling or quantitative data are provided in the abstract.
Cited by
- supports There is a lack of good quality human clinical evidence demonstrating the efficacy of BPC-157 for injury repair.